Oriola Oyj - Income Statement
Oriola Oyj
Helsinki OMXH


Income Statement

Oriola's revenue growth in the last quarter was driven by a 5.3% increase in invoicing, primarily due to strong demand in the Services segment. However, the company's net sales growth was more modest, rising by only 1.7% in the quarter, indicating some challenges in translating invoicing growth into sales. The Services segment, which accounts for a significant portion of Oriola's revenue, experienced a decline in net sales, largely due to weak performance in pharmaceutical distribution in Sweden and advisory services. Despite these headwinds, Oriola's invoicing growth suggests that the company's business is still expanding, and the company's ability to maintain this momentum will be crucial for future growth. Looking ahead, Oriola's revenue development is likely to be influenced by its ongoing efforts to improve operational efficiency and adapt to changing market conditions, particularly in the Services segment.

The realised revenue for Q2 2026 is 51.8 million Euros, and the predicted revenue for Q2 2027 (e) is also 51.8 million Euros. The revenue is expected to remain the same in one year, resulting in no change in millions, and a 0% change in percentage. The revenue is expected to decrease by 1.701 million Euros from 2025 to 2026, which is a 89.4% decrease. From 2026 to 2027, the revenue is expected to increase by 1.997 million Euros, which is a 884.6% increase. The annual revenue values are 1.906 million Euros in 2025, 0.205 million Euros in 2026, and 2.072 million Euros in 2027.





Oriola's EBIT profitability has demonstrated a mixed trend, with a notable increase in the second quarter of 2026, driven by improved operational efficiency and cost management. However, the first half of 2026 saw a decline in EBIT profitability, primarily due to significant ERP investment-related implementation costs and exchange rate differences. Despite these headwinds, Oriola's management has made efforts to optimize its cost structure, which has contributed to the improved EBIT profitability in the second quarter. The company's ability to navigate the challenges posed by the ERP investment and exchange rate fluctuations will be crucial in sustaining its EBIT profitability going forward. Overall, Oriola's EBIT profitability remains a key area of focus for the company, and its management will need to continue to prioritize cost management and operational efficiency to drive long-term growth.

The realised Ebit for Q2 2026 is 0.7 million Euros, while the predicted Ebit for Q2 2027 (e) is -3.0 million Euros. The expected change in Ebit from Q2 2026 to Q2 2027 (e) is a decrease of 3.7 million Euros, which represents a decline of 526.43% compared to the realised value. The expected change in Ebit from 2025 to 2026 is a decrease of 2.5 million Euros, which translates to a percentage decrease of 100%. From 2026 to 2027, the expected change is a decrease of 11.6 million Euros, which is a percentage decrease of 2300%. The annual Ebit values for the respective years are 2.5 million Euros, -0.5 million Euros, and -12.1 million Euros.





The realised value of Profit before tax in Q2 2026 is -1.5 million Euros, and the predicted value for Q2 2027 (e) is -3.0 million Euros. The expected change in one year is a decrease of 1.5 million Euros, which is a 100% increase in the negative value. The change in Profit before tax from 2025 to 2026 is an increase of 0.4 million Euros, which is a 5.1% improvement. From 2026 to 2027, the change is a decrease of 5.6 million Euros, representing a 85.4% drop. The annual values for Profit before tax are -7.9 million Euros in 2025, -6.5 million Euros in 2026, and -12.1 million Euros in 2027.



The realised profit for Q2 2026 is -1.3 million Euros, while the predicted profit for Q2 2027 (e) is -2.4 million Euros. The expected change in profit from Q2 2026 to Q2 2027 (e) is a decrease of 0.1 million Euros, which translates to a percentage decrease of approximately 7.7%. The profit is expected to decrease by 2.6 million Euros from 2025 to 2026, which is a 31% change. From 2026 to 2027, the profit is expected to decrease by 4.1 million Euros, which is a 71% change. The annual profit values are -8.4 million Euros in 2025, -5.8 million Euros in 2026, and -9.7 million Euros in 2027.





Optomed Oyj Orion Oyj










Disclaimer

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.

Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.

The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Contact: quant@quantfactory.eu

About Us